Cargando…

Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis

PURPOSE: The objective was to evaluate the clinical results obtained from the use of immunosafe plasma rich in growth factors (isPRGF) in the treatment of patients with cicatrizing conjunctivitis (CC) who had not responded to the usual therapy. PATIENTS AND METHODS: This is a retrospective study tha...

Descripción completa

Detalles Bibliográficos
Autores principales: de la Sen-Corcuera, Borja, Montero-Iruzubieta, Jesús, Sánchez-Ávila, Ronald M, Orive, Gorka, Anitua, Eduardo, Caro-Magdaleno, Manuel, Merayo-Lloves, Jesús
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306461/
https://www.ncbi.nlm.nih.gov/pubmed/32606577
http://dx.doi.org/10.2147/OPTH.S252253
_version_ 1783548657104060416
author de la Sen-Corcuera, Borja
Montero-Iruzubieta, Jesús
Sánchez-Ávila, Ronald M
Orive, Gorka
Anitua, Eduardo
Caro-Magdaleno, Manuel
Merayo-Lloves, Jesús
author_facet de la Sen-Corcuera, Borja
Montero-Iruzubieta, Jesús
Sánchez-Ávila, Ronald M
Orive, Gorka
Anitua, Eduardo
Caro-Magdaleno, Manuel
Merayo-Lloves, Jesús
author_sort de la Sen-Corcuera, Borja
collection PubMed
description PURPOSE: The objective was to evaluate the clinical results obtained from the use of immunosafe plasma rich in growth factors (isPRGF) in the treatment of patients with cicatrizing conjunctivitis (CC) who had not responded to the usual therapy. PATIENTS AND METHODS: This is a retrospective study that included patients diagnosed with CC, in whom isPRGF was used in different phases (I: eye drops; II: eye drops and injectable; III: eye drops, injectable and surgical treatment) to achieve control of the inflammation. As a clinical follow-up of the patients, the better corrected visual acuity (BCVA), degree of inflammation (measured from 1 to 4), the severity of the CC, Schirmer I test, IOP and TBUT were analyzed. The adverse events were also evaluated. RESULTS: Ten eyes (6 patients) were evaluated, 50% corresponded to Stevens–Johnson Syndrome and 50% to ocular mucous membrane pemphigoid. The mean age was 59.7 ± 16.5 (39–80) years, and 50% were women. Fifty per cent of the cases were initially considered severe CC, and 10% of the cases (one eye of one patient) were considered severe CC at the end of the treatment (p = 0.046). The initial degree of inflammation was 2 in 4 eyes, 3 in two eyes, and 4 in 4 eyes, and final inflammation degree was 1 in all cases (p = 0.004). Twenty per cent of the cases achieved stability in Phase I of the treatment with immunosafe PRGF, 70% with both Phases I and II, and only one case underwent Phase III to achieve stability. The IOP improved significantly (p = 0.027) though the BCVA, TBUT and Schirmer I test showed no significant changes. The follow-up time was 23.1 ± 6.7 (13.6–30.3) months. No adverse effects were reported. CONCLUSION: Treatment with PRGF technology in its injectable and topical immunosafe formulations may be a novel alternative for the treatment of patients with CC, given its complement activity modulating effect, as well as its anti-inflammatory, antifibrotic and regenerative properties.
format Online
Article
Text
id pubmed-7306461
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-73064612020-06-29 Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis de la Sen-Corcuera, Borja Montero-Iruzubieta, Jesús Sánchez-Ávila, Ronald M Orive, Gorka Anitua, Eduardo Caro-Magdaleno, Manuel Merayo-Lloves, Jesús Clin Ophthalmol Original Research PURPOSE: The objective was to evaluate the clinical results obtained from the use of immunosafe plasma rich in growth factors (isPRGF) in the treatment of patients with cicatrizing conjunctivitis (CC) who had not responded to the usual therapy. PATIENTS AND METHODS: This is a retrospective study that included patients diagnosed with CC, in whom isPRGF was used in different phases (I: eye drops; II: eye drops and injectable; III: eye drops, injectable and surgical treatment) to achieve control of the inflammation. As a clinical follow-up of the patients, the better corrected visual acuity (BCVA), degree of inflammation (measured from 1 to 4), the severity of the CC, Schirmer I test, IOP and TBUT were analyzed. The adverse events were also evaluated. RESULTS: Ten eyes (6 patients) were evaluated, 50% corresponded to Stevens–Johnson Syndrome and 50% to ocular mucous membrane pemphigoid. The mean age was 59.7 ± 16.5 (39–80) years, and 50% were women. Fifty per cent of the cases were initially considered severe CC, and 10% of the cases (one eye of one patient) were considered severe CC at the end of the treatment (p = 0.046). The initial degree of inflammation was 2 in 4 eyes, 3 in two eyes, and 4 in 4 eyes, and final inflammation degree was 1 in all cases (p = 0.004). Twenty per cent of the cases achieved stability in Phase I of the treatment with immunosafe PRGF, 70% with both Phases I and II, and only one case underwent Phase III to achieve stability. The IOP improved significantly (p = 0.027) though the BCVA, TBUT and Schirmer I test showed no significant changes. The follow-up time was 23.1 ± 6.7 (13.6–30.3) months. No adverse effects were reported. CONCLUSION: Treatment with PRGF technology in its injectable and topical immunosafe formulations may be a novel alternative for the treatment of patients with CC, given its complement activity modulating effect, as well as its anti-inflammatory, antifibrotic and regenerative properties. Dove 2020-06-17 /pmc/articles/PMC7306461/ /pubmed/32606577 http://dx.doi.org/10.2147/OPTH.S252253 Text en © 2020 de la Sen-Corcuera et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
de la Sen-Corcuera, Borja
Montero-Iruzubieta, Jesús
Sánchez-Ávila, Ronald M
Orive, Gorka
Anitua, Eduardo
Caro-Magdaleno, Manuel
Merayo-Lloves, Jesús
Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis
title Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis
title_full Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis
title_fullStr Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis
title_full_unstemmed Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis
title_short Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis
title_sort plasma rich in growth factors for the treatment of cicatrizing conjunctivitis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306461/
https://www.ncbi.nlm.nih.gov/pubmed/32606577
http://dx.doi.org/10.2147/OPTH.S252253
work_keys_str_mv AT delasencorcueraborja plasmarichingrowthfactorsforthetreatmentofcicatrizingconjunctivitis
AT monteroiruzubietajesus plasmarichingrowthfactorsforthetreatmentofcicatrizingconjunctivitis
AT sanchezavilaronaldm plasmarichingrowthfactorsforthetreatmentofcicatrizingconjunctivitis
AT orivegorka plasmarichingrowthfactorsforthetreatmentofcicatrizingconjunctivitis
AT anituaeduardo plasmarichingrowthfactorsforthetreatmentofcicatrizingconjunctivitis
AT caromagdalenomanuel plasmarichingrowthfactorsforthetreatmentofcicatrizingconjunctivitis
AT merayollovesjesus plasmarichingrowthfactorsforthetreatmentofcicatrizingconjunctivitis